医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

2021年03月11日 AM06:30
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, Mass. & BEIJING

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, including three oral presentations to highlight clinical data on anti-PD-1 antibody tislelizumab and on investigational spectrum-selective kinase inhibitor sitravatinib in combination with tislelizumab, and one poster presentation of preclinical data on its investigational anti-TIGIT antibody ociperlimab (BGB-A1217). The AACR Annual Meeting will take place in a virtual format on April 10-15 and May 17-21, 2021.

Oral Presentations:

Title:

Results from RATIONALE 303: A global Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC

Presentation #:

CT039

Session Title:

Disease-Oriented Innovative Clinical Research and Trials

Date and Time:

Monday, April 12, 2021 at 1:30 – 3:15 p.m. ET

Presenter:

Professor Caicun Zhou, Shanghai Pulmonary Hospital, China

 

Title:

Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)

Presentation #:

CT013

Session Title:

Targeted Therapy and Ovarian Cancer Trials

Date and Time:

Sunday, April 11, 2021 at 2:00 – 3:45 p.m. ET

Presenter:

Jeffrey Goh, MBBS, FRACP, Icon Cancer Centre, Australia

 

Title:

Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study

Presentation #:

CT035

Session Title:

Clinical Trials with Novel Immuno-Oncology Strategies

Date and Time:

Sunday, April 11, 2021 at 4:00 – 5:45 p.m. ET

Presenter:

Professor Chuanliang Cui, Beijing Cancer Hospital, China

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005917/en/

CONTACT

Investor Contact

Craig West

+1 857-302-5189

ir@beigene.com

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or +1 857-302-7596

media@beigene.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease